Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 21 Breast 12 Other hematologic neoplasm 10 Sarcoma 5 Genitourinary 4 CNS 4 Thoracic 3 Gynecologic 3 Plasma cell 2 Head & Neck 1 Gastrointestinal 1 Endocrine 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 297 Fluorouracil 272 Bevacizumab 235 Gemcitabine 234 Leucovorin 212 Capecitabine 204 pembrolizumab 200 Nivolumab 157 Irinotecan 156 Cisplatin 148 Specimen Handling 143 Magnetic Resonance Spectroscopy 130 130-nm albumin-bound paclitaxel 115 Paclitaxel 109 durvalumab 104 Cetuximab 102 Radiotherapy 96 atezolizumab 92 Biopsy 92 Drug Therapy 91 Albumin-Bound Paclitaxel 78 tislelizumab 77 Taxes 73 Folfox protocol 68 lenvatinib 67 Carboplatin 65 regorafenib 60 Blood Specimen Collection 60 trifluridine tipiracil drug combination 52 Ipilimumab 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

pegfilgrastim × Gastrointestinal × 1 year × Clear all

NCT06094140 2026-05-06

NEO-IMPACT

Australasian Gastro-Intestinal Trials Group

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡